Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant

Abstract

The potential benefits of synthetic factor VIIa when compared with conventional therapy with fresh frozen plasma are discussed. Previous experience with synthetic factor VIIa in pediatric-aged patients and the cardiothoracic surgical population is presented.